Determining the Patent Status of Essential Medicines in Developing Countries - Health Economics and Drugs Series No. 017
(2004; 24 pages)

Resumen
Despite the fact that flexibility in the TRIPS Agreement is now widely recognized, most developing countries have not made use of the safeguard measures. For instance, while compulsory licences in respect of pharmaceutical and other patents are routinely granted in developed countries, there have been very few, if any, in the developing countries. A crucial aspect of the decision-making process is the availability of accurate and up-to-date information about the patent status of essential medicines. There have been calls for such patent data to collected and presented in a transparent and public form…
Documentos relacionados
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019